Meeting
2021 ASCO Annual Meeting
Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
Authors
Eric S. Nadler
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
Eric S. Nadler , Anupama Vasudevan , Kalatu Davies , Yunfei Wang , Ann Johnson , Sarika Ogale
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8561)
DOI
10.1200/JCO.2021.39.15_suppl.8561
Abstract #
8561
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Burden of myelosuppression in extensive-stage small-cell lung cancer patients receiving chemotherapy: Retrospective analysis of real-world data from Tennessee Oncology.
First Author: L. Johnetta Blakely
Poster
2021 ASCO Quality Care Symposium
Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States.
First Author: Jinan Liu
Poster
2020 ASCO Virtual Scientific Program
A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06).
First Author: Amy Lauren Cummings
Poster
2024 ASCO Annual Meeting
Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study.
First Author: Heya Batah